Journal
BIOMOLECULES
Volume 12, Issue 12, Pages -Publisher
MDPI
DOI: 10.3390/biom12121782
Keywords
multi-omics networks; hub genes; CRISPR-Cas9; RNAi; proliferation; non-small cell lung cancer; patient survival; biomarkers; therapeutic targets
Categories
Ask authors/readers for more resources
Currently, there are no accurate biomarkers for optimal treatment selection in early-stage non-small cell lung cancer (NSCLC). This study demonstrates that hub genes in genome-scale regulatory networks are associated with NSCLC tumorigenesis, proliferation, and survival. These findings have implications for prioritizing therapeutic targets to improve patient survival outcomes.
There are currently no accurate biomarkers for optimal treatment selection in early-stage non-small cell lung cancer (NSCLC). Novel therapeutic targets are needed to improve NSCLC survival outcomes. This study systematically evaluated the association between genome-scale regulatory network centralities and NSCLC tumorigenesis, proliferation, and survival in early-stage NSCLC patients. Boolean implication networks were used to construct multimodal networks using patient DNA copy number variation, mRNA, and protein expression profiles. T statistics of differential gene/protein expression in tumors versus non-cancerous adjacent tissues, dependency scores in in vitro CRISPR-Cas9/RNA interference (RNAi) screening of human NSCLC cell lines, and hazard ratios in univariate Cox modeling of the Cancer Genome Atlas (TCGA) NSCLC patients were correlated with graph theory centrality metrics. Hub genes in multi-omics networks involving gene/protein expression were associated with oncogenic, proliferative potentials and poor patient survival outcomes (p < 0.05, Pearson's correlation). Immunotherapy targets PD1, PDL1, CTLA4, and CD27 were ranked as top hub genes within the 10th percentile in most constructed multi-omics networks. BUB3, DNM1L, EIF2S1, KPNB1, NMT1, PGAM1, and STRAP were discovered as important hub genes in NSCLC proliferation with oncogenic potential. These results support the importance of hub genes in NSCLC tumorigenesis, proliferation, and prognosis, with implications in prioritizing therapeutic targets to improve patient survival outcomes.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available